Synlogic, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SYBX research report →
Companywww.synlogictx.com
Synlogic, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria.
- CEO
- Mary Beth Dooley
- IPO
- 2015
- Employees
- 1
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $7.72M
- P/E
- -12.76
- P/S
- 0.00
- P/B
- 0.65
- EV/EBITDA
- 1.62
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -5.42%
- ROIC
- -36.84%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-1,005,000 · 95.70%
- EPS
- $-0.08 · 95.83%
- Op Income
- $-4,008,000
- FCF YoY
- 86.24%
Performance & Tape
- 52W High
- $1.96
- 52W Low
- $0.54
- 50D MA
- $0.64
- 200D MA
- $1.12
- Beta
- 0.52
- Avg Volume
- 13.45K
Get TickerSpark's AI analysis on SYBX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 29, 25 | Dooley Mary Beth | sell | 157 |
| Apr 26, 25 | Shea Richard P | other | 15,000 |
| Apr 26, 25 | Flynn James P | other | 15,000 |
| Apr 2, 25 | Dooley Mary Beth | sell | 144 |
| Feb 3, 25 | Dooley Mary Beth | sell | 2,107 |
| Oct 29, 24 | Dooley Mary Beth | sell | 79 |
| Apr 2, 24 | Dooley Mary Beth | sell | 188 |
| Apr 2, 24 | Awad Antoine | sell | 372 |
| Mar 18, 24 | Dooley Mary Beth | other | 0 |
| Mar 18, 24 | Dooley Mary Beth | other | 3,612 |
Our SYBX Coverage
We haven't published any research on SYBX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SYBX Report →